Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Net Assets

Latest as of March 2026: CN¥12.23 Billion CNY ≈ $1.79 Billion USD

Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has net assets worth CN¥12.23 Billion CNY (≈ $1.79 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.01 Billion ≈ $2.49 Billion USD) and total liabilities (CN¥4.78 Billion ≈ $700.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shenzhen Hepalink Pharmaceutical Co Ltd (002399) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥12.23 Billion
% of Total Assets	71.88%
Annual Growth Rate	29.32%
5-Year Change	4.83%
10-Year Change	49.35%
Growth Volatility	151.6

Shenzhen Hepalink Pharmaceutical Co Ltd - Net Assets Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Shenzhen Hepalink Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual net assets of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. For live valuation and market cap data, see Shenzhen Hepalink Pharmaceutical Co Ltd market cap and net worth.

Year	Net Assets	Change
2025-12-31	CN¥12.08 Billion ≈ $1.77 Billion	-1.00%
2024-12-31	CN¥12.20 Billion ≈ $1.79 Billion	+1.78%
2023-12-31	CN¥11.99 Billion ≈ $1.75 Billion	-3.38%
2022-12-31	CN¥12.41 Billion ≈ $1.82 Billion	+7.67%
2021-12-31	CN¥11.52 Billion ≈ $1.69 Billion	-1.42%
2020-12-31	CN¥11.69 Billion ≈ $1.71 Billion	+56.46%
2019-12-31	CN¥7.47 Billion ≈ $1.09 Billion	+19.64%
2018-12-31	CN¥6.24 Billion ≈ $913.80 Million	-18.76%
2017-12-31	CN¥7.69 Billion ≈ $1.12 Billion	-4.97%
2016-12-31	CN¥8.09 Billion ≈ $1.18 Billion	-8.01%
2015-12-31	CN¥8.79 Billion ≈ $1.29 Billion	+5.27%
2014-12-31	CN¥8.35 Billion ≈ $1.22 Billion	+3.53%
2013-12-31	CN¥8.07 Billion ≈ $1.18 Billion	+0.28%
2012-12-31	CN¥8.05 Billion ≈ $1.18 Billion	+1.66%
2011-12-31	CN¥7.91 Billion ≈ $1.16 Billion	-1.36%
2010-12-31	CN¥8.02 Billion ≈ $1.17 Billion	+649.66%
2009-12-31	CN¥1.07 Billion ≈ $156.62 Million	+247.68%
2008-12-31	CN¥307.83 Million ≈ $45.05 Million	+110.21%
2007-12-31	CN¥146.44 Million ≈ $21.43 Million	+60.34%
2006-12-31	CN¥91.33 Million ≈ $13.36 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Hepalink Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10448.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥4.02 Billion	33.42%
Other Components	CN¥8.01 Billion	66.58%
Total Equity	CN¥12.03 Billion	100.00%

Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Bank First National Corp NASDAQ:BFC	$1.60 Billion
Wondershare Technology Co Ltd Class A SHE:300624	$1.60 Billion
Harbin Hatou Investment Co Ltd SHG:600864	$1.60 Billion
AKSO HEALTH GR. (SPADR)/3 F:8HX	$1.60 Billion
Ninety One PLC JSE:N91	$1.60 Billion
Dynamic Holding Co. Ltd. TW:3715	$1.60 Billion
Tung Ho Steel Enterprise Corp TW:2006	$1.60 Billion
Graubuendner Kantonalbank SW:GRKP	$1.60 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Hepalink Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 12,148,672,778 to 12,030,940,527, a change of -117,732,251 (-1.0%).
Net income of 349,485,812 contributed positively to equity growth.
Dividend payments of 430,809,733 reduced retained earnings.
Other comprehensive income decreased equity by 962,559,199.
Other factors increased equity by 926,150,870.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥349.49 Million	+2.9%
Dividends Paid	CN¥430.81 Million	-3.58%
Other Comprehensive Income	CN¥-962.56 Million	-8.0%
Other Changes	CN¥926.15 Million	+7.7%
Total Change	CN¥-	-0.97%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Hepalink Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.07x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 27.71x to 1.07x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.32	CN¥8.77	x
2007-12-31	CN¥0.51	CN¥8.77	x
2008-12-31	CN¥1.07	CN¥8.77	x
2009-12-31	CN¥0.93	CN¥8.77	x
2010-12-31	CN¥12.93	CN¥8.77	x
2011-12-31	CN¥6.13	CN¥8.77	x
2012-12-31	CN¥6.22	CN¥8.77	x
2013-12-31	CN¥6.24	CN¥8.77	x
2014-12-31	CN¥6.46	CN¥8.77	x
2015-12-31	CN¥6.88	CN¥8.77	x
2016-12-31	CN¥6.36	CN¥8.77	x
2017-12-31	CN¥6.08	CN¥8.77	x
2018-12-31	CN¥4.87	CN¥8.77	x
2019-12-31	CN¥5.89	CN¥8.77	x
2020-12-31	CN¥8.55	CN¥8.77	x
2021-12-31	CN¥7.78	CN¥8.77	x
2022-12-31	CN¥8.39	CN¥8.77	x
2023-12-31	CN¥8.06	CN¥8.77	x
2024-12-31	CN¥8.27	CN¥8.77	x
2025-12-31	CN¥8.20	CN¥8.77	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Hepalink Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 2.90%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 6.38%
• Asset Turnover: 0.33x
• Equity Multiplier: 1.38x
Recent ROE (2.90%) is below the historical average (16.16%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	52.43%	17.24%	0.80x	3.82x	CN¥38.75 Million
2007	46.55%	22.77%	1.16x	1.76x	CN¥53.52 Million
2008	52.43%	37.08%	0.75x	1.88x	CN¥130.61 Million
2009	75.98%	36.38%	1.62x	1.29x	CN¥702.57 Million
2010	15.13%	31.39%	0.47x	1.02x	CN¥410.32 Million
2011	7.96%	24.94%	0.31x	1.02x	CN¥-159.56 Million
2012	7.84%	35.44%	0.21x	1.04x	CN¥-171.76 Million
2013	3.97%	20.97%	0.18x	1.04x	CN¥-481.27 Million
2014	4.09%	17.27%	0.20x	1.20x	CN¥-488.70 Million
2015	6.65%	25.29%	0.19x	1.40x	CN¥-292.13 Million
2016	4.98%	17.55%	0.18x	1.62x	CN¥-400.23 Million
2017	2.59%	6.92%	0.22x	1.74x	CN¥-561.38 Million
2018	9.75%	12.28%	0.35x	2.25x	CN¥-15.34 Million
2019	14.42%	22.91%	0.30x	2.07x	CN¥324.65 Million
2020	8.85%	19.21%	0.28x	1.64x	CN¥-132.73 Million
2021	2.11%	3.78%	0.33x	1.67x	CN¥-900.35 Million
2022	5.91%	10.16%	0.34x	1.69x	CN¥-503.67 Million
2023	-6.57%	-14.42%	0.28x	1.61x	CN¥-1.97 Billion
2024	5.32%	12.30%	0.30x	1.43x	CN¥-568.13 Million
2025	2.90%	6.38%	0.33x	1.38x	CN¥-853.61 Million

Industry Comparison

This section compares Shenzhen Hepalink Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,988,841
Average return on equity (ROE) among peers: 4.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shenzhen Hepalink Pharmaceutical Co Ltd (002399)	CN¥12.23 Billion	52.43%	0.39x	$1.60 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$654.09 Million	2.17%	0.78x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$0.00	0.00%	0.00x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$973.90 Million	0.17%	0.60x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$3.19 Billion	14.61%	0.55x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$353.98 Million	-9.58%	0.80x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$307.22 Million	6.68%	0.79x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$2.55 Billion	4.67%	3.16x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$25.04 Billion	7.11%	0.16x	$3.00 Billion

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.60 Billion

CN¥10.94 Billion CNY

Market Cap Rank

#7116 Global

#1627 in China

Share Price

CN¥8.77

Change (1 day)

-3.20%

52-Week Range

CN¥8.77 - CN¥13.88

All Time High

CN¥28.69